NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Olanzapine Based Dexamethasone-sparing Regimen for Breast Cancer Patients With Metabolic-risk Factors

RecruitingNA

Sponsor: Alexandria University

Conditions: Olanzapine, Breast Cancer, Dexamethasone

Interventions: Pantoprazole, olanzapine, Dexamethasone

Countries: Egypt

The aim of THE STUDY to determine whether an olanzapine-based dexamethasone-sparing antiemetic regimen is non-inferior to the standard dexamethasone-containing regimen in preventing delayed-phase Chemotherapy-induced nausea and vomiting while reducing metabolic toxicity in breast cancer patients with metabolic risk factors.

Eligibility overview

Sex: FEMALE

Age: 18 Years to 70 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Female patients ≥18 years.
* Stage I-III breast cancer.
* Scheduled to receive AC chemotherapy.
* Presence of metabolic risk factors (diabetes, prediabetes, obesity, metabolic syndrome).
* ECOG performance status ≤2.

Exclusion Criteria:

* Recent systemic corticosteroid use.
* Active nausea or vomiting before chemotherapy.
* Severe renal or hepatic impairment.
* Uncontrolled diabetes or hypertension.
* Psychiatric illness affecting adherence.
* Pregnancy or lactation.
* Active infections or inflammatory diseases.
* Participation in another clinical trial

Locations (1)

Alexandria, Alexandria Governorate, Egypt